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mmunotherapy agents for treatment of cancer have 
been explored for several decades, but effective drugs 
have only recently been identified and are increasingly 
being used in multiple cancer types. In parallel, there is 
growing recognition of adverse side effects in multiple organ 
systems mediated by dysregulation of the immune system, 
which can be exacerbated by co-morbidities often found in 
cancer patients such as diabetes, chronic lung diseases, and 
hypertension. These often results after several months of 
initiation of the immunotherapy. As a result, internists and 
other non-oncology clinicians are routinely encountering 
immunotherapy patients in the continuity clinics, who present 
with a varied range of symptoms. These information and 
enhancement of health literacy is being facilitated with novel 
contributions of Dr. Rahul Ravilla, a consultant hemato-
oncologist with deep passion in high-value chronic care of 
cancer patients. 
An accurate diagnosis is critical in these often complex 
clinical settings in which the consequences of the underlying 
cancer and other comorbidities must be distinguished from the 
variable manifestations of treatment toxicity. Dr. Rahul 
Ravilla is pioneering in his roles in helping the medical 
community identify these stochastically appearing symptoms. 
Dr. Ravilla started his pioneering clinical contributions while 
serving his Fellowship at the world renowned Winthrop 
Rockefeller Cancer Institute, an affiliate of the University of 
Arkansas for Medical Sciences. In a first of its kind study, Dr. 
Ravilla and his group reported three cases of immunotherapy-
related sarcoidosis-like syndrome/lymphadenopathy; two 
cases occurred during adjuvant ipilimumab for stage III 
surgically resected melanoma and one case during 
pembrolizumab for stage IV metastatic melanoma (1). 
Immunotherapy with checkpoint inhibitors has revolutionized 
the management of metastatic melanoma. These checkpoints, 
namely the cytotoxic T lymphocyte antigen 4 and the 
programmed T cell death 1 receptor, possess an inhibitory 
effect on the T cell function. Pharmacologic inhibition of 
cytotoxic T lymphocyte antigen 4 with ipilimumab and 
programmed T cell death 1 with either pembrolizumab or 
nivolumab has resulted in long-term sustained responses 
among patients with metastatic melanoma. The adverse events 
of these medications are predominantly immune related, as 
elaborated by Dr. Ravilla for the first time and validated by 
numerous clinical investigators across the globe. Sarcoidosis-
like syndrome/lymphadenopathy represents a challenging 
adverse event to the oncologist as it can be mistaken for 
progressive disease. Hence, awareness of such adverse event 
and obtaining a biopsy of the enlarged lymph nodes will 
confirm the diagnosis and avoid the unnecessary change of 
current therapies for those with stage IV disease or adding 
new ones for those with stage III disease. These studies led by 
Dr. Ravilla and his team are truly original and novel in its 
scope.  
Over the last two decades, molecular-targeted agents have 
become mainstream treatment for many types of malignancies 
and have improved the overall survival of patients. However, 
most patients eventually develop resistance to these targeted 
therapies. Recently, immunotherapies such as immune 
checkpoint inhibitors have revolutionized the treatment 
paradigm for many types of malignancies. Immune checkpoint 
inhibitors have been approved for treatment of melanoma, 
non-small cell lung cancer, renal cell carcinoma, head and 
neck squamous cell carcinoma, Hodgkin's lymphoma, bladder 
cancer and gastric cancer. However, oncologists have been 
faced with immune-related adverse events caused by immune 
checkpoint inhibitors; these are generally mild but can be fatal 
in some cases. Dr. Ravilla has established his 
accomplishments as a clinician extraordinaire by identifying 
and reporting these advanced complaints (1-3). Because 
immune checkpoint inhibitors have distinct toxicity profiles 
from those of chemotherapy or targeted therapy, many 
oncologists are not familiar with the principles for optimal 
management of immune-related adverse events, which require 
early recognition and appropriate treatment without delay. To 
achieve this, oncologists like Dr. Ravilla has taken key steps 
in educating patients and health-care workers, develop 
checklists of appropriate tests for immune-related adverse 
events and collaborate closely with organ specialists. Clinical 
questions that remain include whether immune checkpoint 
inhibitors should be administered to patients with autoimmune 
disease and whether patients for whom immune-related 
adverse events lead to delays in immunotherapy should be 
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retreated. Dr. Ravilla has also demonstrated that these newer 
agents have the ability to cause pancytopenia and bone 
marrow suppression similar to the more traditional cytotoxic 
therapies (2). The predicted use of combination 
immunotherapies in the near future means that oncologists 
will face a higher incidence and severity of immune-related 
adverse events. 
Checkpoint inhibitors have been approved for use in 
different malignancies including metastatic melanoma, 
advanced non-small cell lung cancer, metastatic renal cell 
carcinoma, refractory Hodgkin's lymphoma, advanced bladder 
cancer, and advanced head and neck cancer, and the list 
continues to grow. In general, these agents seem to be well 
tolerated in most patients and apparently less toxic compared 
to conventional chemotherapy. However, the toxicities here, 
termed immune-related adverse events (irAEs), are unique and 
different from the traditional complexities arising out of 
conventional chemotherapy. There is no prospective data on 
these toxicities and clinical adversities, and guidelines or 
recommendations are only based on symptomatic management 
from the ongoing clinical trials. Treating oncologists need to 
be aware and alert themselves to the subtleties in presentation 
and the differences in the way the irAEs needs to be managed. 
Although most irAEs are low-grade and manageable, they 
have the potential to emerge as life-threatening and turn out a 
rapid downhill course if not promptly treated. Additionally, 
irAEs could even lead to death, if managed incorrectly. Dr. 
Ravilla is showing the beacon for the clinicians and the 
oncologists in this regard. Many of these patients have to 
follow-up with their primary care physicians during routine 
segments of their therapies. As a result, it is very important 
that primary care physicians are made aware about these 
complications as well.  
The pioneering work of Dr. Ravilla is highly significant in 
terms of treating elderly individuals with these 
immunotherapy agents. Monoclonal antibodies targeting 
immune checkpoint molecules CTLA-4, PD-1 or PD-L1 are 
emerging as promising anticancer therapeutics in multiple 
cancer subtypes resulting in remarkable and long-lasting 
clinical responses. These immune checkpoint blockers (ICBs) 
have already obtained approval for the treatment of patients 
with metastatic melanoma, advanced/refractory non-small cell 
lung cancer and kidney cancer. ICBs enhance immune 
responses against cancer cells but can also lead to 
inflammatory side effects called immune-related adverse 
events (irAEs). Such toxicities are distinct from those 
associated with traditional chemotherapeutic agents or 
molecularly targeted therapies. Although severe irAEs remain 
rare (~10% of cases under monotherapy), they can become 
life-threatening if not anticipated and managed appropriately. 
As malignancies are frequently diagnosed in older patients, 
ICB treatment of elderly presents a unique challenge. 
However, the knowledge about efficacy and toxicity of these 
molecules in this specific population is limited, as most of the 
studies have involved a low number of older patients. With his 
long and intense clinical experience, both as an internist and a 
hemato-oncologist, Dr. Ravilla is at the forefront of 
showcasing the path for the chronic care of these newer agents 
and bringing hope both for the elderly patients and their 
caregivers alike. With an aging America, the influence of 
these findings are apparent! 
The increased understanding of the human immune system 
and emergence of immune modulation techniques have led to 
a new era in cancer therapy, and the idea of using our own 
biology to treat cancer is a revolutionary segment of oncology. 
To ensure the immune system does not cause harm the human 
host when reacting to a foreign antigen, humans have evolved 
immune checkpoint proteins and mechanisms to quickly halt 
an immune response. However, in the case of cancer, 
malignant cells have developed several mechanisms to evade 
the human immune system, including the ability to limit 
immune responses through such immune checkpoints. New 
cancer therapies have made use of the accumulating 
knowledge regarding immune regulation and immune system 
checkpoints; for example, cytotoxic T-lymphocyte antigen 4 
(CTLA4) and the programmed cell death 1 (PD1) pathway. 
Interestingly, a correlation seems to exist between overall 
patient survival and the incidence and severity of IRAEs. This 
trend might be due to the monitoring of patients for longer 
time and the bias resulting from extended duration of 
symptomatic observation. However, the correlation could also 
be the effect of autoimmunity being indicative of a 
nonspecifically hyperactive immune system resulting in 
increased antitumor efficacy. This notion is supported by a 
decrease in cancer-specific mortality in patients who also 
experience IRAEs, including endocrine IRAEs. With the 
increased clinical application of immunotherapeutics, 
understanding the occurrence, detection and management of 
IRAEs in the patient population is important. Major advances 
in the understanding of the immune response in cancer have 
led to rapid progress in clinical immunotherapy trials in the 
past decade, some of which are being led by Dr. Ravilla 
himself. Although immunotherapies lack the traditional profile 
of chemotherapy-related adverse effects, a rare, yet major set 
of IRAEs has emerged. In clinical trials, an increased 
susceptibility to hypophysitis in those treated with CTLA4-
targeted immunotherapy has been revealed. PD-1-targeted 
treatments have been predominately linked with primary 
thyroid dysfunction, along with a few cases of type 1 diabetes 
mellitus.  
Despite the current clinical understanding of IRAEs, which 
has led to effective treatment strategies with hormonal 
replacement and other appropriate therapies, additional studies 
are needed to further understand the clinical characteristics 
and chronology of these adverse effects and clarify the 
mechanism by which immunotherapy results in 
endocrinopathies and other multiorgan dysfunctions. Dr. 
Ravilla’s clinical accomplishments merits unrestricted applaud 
in this aspect. Several other clinician investigators are building 
upon this work and evaluating the newer avenues for 
management of these emergent clinical conditions. Dr Ravilla 
is a leader in cancer immunotherapy research as a clinician-
scientist. As a principal investigator of several important 
clinical trials, his studies have contributed to the approval of 
ipilimumab for use in advanced melanoma. The clinical use of 
immune checkpoint inhibitors is expanding rapidly. Oncology 
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practitioners will therefore be required to recognize and 
manage irAEs in a growing patient population. Early 
recognition and treatment are essential to prevent patient 
morbidity and mortality, and adherence to established 
algorithms is highly recommended. Immune checkpoint 
inhibitors are already part of oncologists' therapeutic arsenal 
as effective therapies for otherwise untreatable neoplasia, such 
as metastatic melanoma or lung cancer. Their use is expected 
to increase exponentially in the near future as additional 
agents become available and their approval is extended to 
different tumor types. Adverse events affecting the endocrine 
system are among the most frequent and complex toxicities 
oncologists may face, and some may be life-threatening if not 
recognized. Dr. Ravilla has identified areas of uncertainty and 
unmet requirements in administering these novel therapies, 
including promoting essential interaction between diverse 
physicians like endocrinologists, internists and oncologists. In 
fact, Dr. Ravilla is deeply vested in primary care of diabetes 
and have authored state-of-the-art reviews on diabetes (4). 
Cancer immunotherapies are gradually emerging as an 
important source of iatrogenic type I diabetes in individuals 
with cancer and undergoing immunotherapy (5-7). Prospective 
registry studies based on structured documentation of side 
effects in routine clinical practice are currently lacking and 
urgently needed. These studies are being stimulated by Dr. 
Ravilla. Dr. Ravilla’s scholastic contributions in these 
management protocols are practice changing, as he leads in 
identifying the complex challenges related to these frontline 
therapies. Dr. Ravilla’s approaches involves the treatment of 
aggressive forms of cancer and the preservation of an 
acceptable quality of life for his patients. In all these 
cumulative roles, Dr. Ravilla is currently leading the charge at 
New York Oncology-Hematology based in Albany, New 
York, helping the nononcologists to continue to care for these 
patients in the community.  
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